its structure elucidation and biological properties including cytotoxic and antimicrobial activities.
The GTRI-BB-producing strain, Micromonospora sp.
SA246, which was already described in the previous study4), was used in this study. Potato-dextrose broth was used for the culture of the microorganism. SA 246 was cultured in 500ml flasks containing each 100ml of the medium for 14 days on a rotary shaker (250rpm) in a 16 mass units higher than 1-or 9-hydroxycrisamicin A.
The various NMR spectra were obtained on a Bruker NMR spectrometer at 400MHz in CDCl3 with TMS as an internal standard. 1H and 13C NMR spectral data of GTRI-BB summarized in Table 1 were almost identical to those of crisamicin A and its hydroxyl derivatives4,5). This suggests that GTRI-BB may be one of crisamicin A derivatives. 1H
NMR of GTRI-BB showed two hydrogen-bonded hydroxyl groups at 11.88 and 11.93ppm, four aromatic methine, seven oxygenated methine, two methylene, and three was calculated. GTRI-BB exhibited stronger inhibitory effect on the growth of the tumor cell lines than adriamycin which is a commercial anticancer compound (Table 2) . GTRI-BB was more cytotoxic than 9-hydroxycrisamicin A,
showing more than twice toxicity to the same kinds of cell lines such as melanoma, lung and colon cancers. This indicates the structural modification may enhance the cytotoxic efficacy.
Specific pathogen-free (SPF) BDFI mice (females, 18-21g) were used as test animals for the anticancer activity of GTRI-BB. Mice were intraperitoneally implanted with B16 melanoma (105 cells/animal), and from 4 hours later, the chemical solutions (0.1mg, 0.3mg and 1.0mg/kg) were intraperitoneally administered daily at 0.2ml per 20g body weight 13 times up to on the 12th day after the cancer cell implementation. For negative and positive controls, 0.8% tween 80 (vehicle alone) and 1mg/kg adriamycin were administered as above. Mortality and body weight changes of treated mice were examined daily and at the intervals of 2 days, respectively, until 30 days after the first treatment. Contrary to the cytotoxic efficacy of GTRI-BB, no significant effect on the survival of mice implanted with B16 melanoma at 3 concentration levels of GTRI-BB (0.1, 0.3 and 1.0mg/kg), while 1mg/kg of adriamycin was very effective for sustaining the survival of mice (survival extension efficacy of 90.2% than the vehicle control). GTRI-BB rather shortened the mouse life span at 1mg/kg concentration, indicating nonspecific toxicity. The mice treated with GTRI-BB or adriamycin showed no significant changes of body weight during the first 12 days except for 1mg/kg of GTRI-BB that showed weight loss for 5 days after treatment compared with the vehicle alone. This suggests that BTRI-BB should have no value as the internal use for antitumorous therapy. However, its high toxicity especially to melanoma may implicate that the compound can be applied topically or locally with a proper delivery system. Antimicrobial activity was determined by paper disc method using Mueller-Hinton agar and potato-dextrose agar (PDA) for bacteria and fungi, respectively. GTRI-BB showed antibiotic activity only against the Gram-positive bacteria tested, but no effect against the Gram-negative bacteria and fungi (Table 3) as in other crisamicin derivatives. This suggests that the secondary structural modification of crisamicin A may be not related to the changes of antimicrobial activity.
